Superior efficacy of automated repositioning chair over bedside canalith repositioning manoeuvre in managing benign paroxysmal positional vertigo: a randomised, multicentre, controlled clinical trial

Background

Canalith repositioning manoeuvre chair (Chair-CRM), equipped with a software-controlled repositioning system, has been employed empirically for the management of Benign Paroxysmal Positional Vertigo (BPPV). yet a comprehensive quantitative evaluation of its efficacy is lacking.

Methods

In this prospective, multicentre, open-label, randomised, parallel group, clinical trial, participants diagnosedwith posterior or horizontal BPPV were randomly allocated in a 1:1 ratio to either undergo the Chair-CRM intervention or receive the manual Canalith Repositioning Maneuver (Bedside-CRM) as the initial treatment.. The primary outcome measure focused on the rate of response (cured and improved) during 1-week follow-up.

Results

Among 404 participants, the response rate was significantly higher in the Chair-CRM group than that in Bedside-CRM group (FAS: 91.54%vs81.77%, P=0.004; PPS: 98.37%vs85.95%, P<0.001) at 1-week post-treatment assessment. The Chair-CRM group exhibited a higher response rate immediately after the initial treatment. The curative rate was significantly higher in the Chair-CRM group in PPSat 1-week follow-up. Chair-CRM group displayed a significantly higher response rate compared to the Bedside-CRM group as well as a higher curative rate. From 2 weeks after initial treatment, participants treated with Chair-CRM or Bedside-CRM maintained elevated curative and response rates. No statistically significant differences were reported in adverse events and laboratory parameters between the two groups during follow-up period.

Conclusions

The Chair-CRM demonstrates a superior therapeutic effect compared to the Bedside-CRM by promptly alleviating symptoms and consistently achieving the resolution of BPPV.

The authors declare that there is no conflict of interest